News
Health Canada approves Descovy for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.- Gilead Sciences
Gilead Sciences' Canada has filed a supplemental marketing application with Health Canada seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV.
Descovy was approved in Canada in 2016 for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg (in combination with other antiretrovirals).
Condition: HIV Prevention
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins